期刊
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
卷 24, 期 -, 页码 129-131出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/14767058.2011.607677
关键词
Neonate; hemostasis; hemorrhage; plasma
Evidence-based indications for the use of plasma products in neonatal medicine are limited to few conditions. In the setting of inherited disorders of hemostasis, fresh frozen plasma (FFP) and cryoprecipitate should be used as replacement therapy only if the specific factor concentrate is not available. FFP is indicated to treat disseminated intravascular coagulation (DIC), liver failure, vitamin K-dependent bleeding and to reconstitute whole blood for exchange transfusion. Despite the lack of evidence, the use of cryoprecipitate to treat neonates with acquired hypofibrinogenemia during DIC or liver failure is now considered standard therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据